1. Home
  2. ESQ vs AKBA Comparison

ESQ vs AKBA Comparison

Compare ESQ & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Esquire Financial Holdings Inc.

ESQ

Esquire Financial Holdings Inc.

HOLD

Current Price

$108.17

Market Cap

910.9M

Sector

Finance

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.42

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESQ
AKBA
Founded
2006
2007
Country
United States
United States
Employees
151
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
910.9M
729.1M
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
ESQ
AKBA
Price
$108.17
$1.42
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$120.33
$5.75
AVG Volume (30 Days)
71.3K
2.6M
Earning Date
04-23-2026
05-07-2026
Dividend Yield
0.76%
N/A
EPS Growth
14.20
93.94
EPS
5.87
N/A
Revenue
N/A
N/A
Revenue This Year
$28.65
N/A
Revenue Next Year
$4.95
N/A
P/E Ratio
$17.97
N/A
Revenue Growth
N/A
N/A
52 Week Low
$69.14
$1.14
52 Week High
$119.86
$4.08

Technical Indicators

Market Signals
Indicator
ESQ
AKBA
Relative Strength Index (RSI) 54.55 54.11
Support Level $91.62 $1.30
Resistance Level $112.17 $1.52
Average True Range (ATR) 3.81 0.07
MACD 0.66 0.01
Stochastic Oscillator 65.46 61.84

Price Performance

Historical Comparison
ESQ
AKBA

About ESQ Esquire Financial Holdings Inc.

Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: